Although preclinical studies suggest that PD-1 blockade (e.g., with nivolumab) may restore IL-10 function, the potential autoimmune risks associated with such interventions in COPD patients warrant cautious interpretation. This evidence concerns the gene PDCD1 and chronic obstructive pulmonary disease.